4SC AG (VSC) - Financial and Strategic SWOT Analysis Review

4SC AG (VSC) - Financial and Strategic SWOT Analysis Review

  • July 2017
  • 43 pages
  • GlobalData
Report ID: 343887
4SC AG (VSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights
4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at various stages of clinical development and early-stage research projects including resminostat, 4SC-202, and 4SC-208. The company’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. It develops and markets products through partnerships with pharmaceutical and biotech companies. The company operates through its subsidiary 4SC Discovery GmbH. 4SC is headquartered in Bayern, Germany.

4SC AG Key Recent Developments
Nov 10,2016: 4SC provides Q3 2016 update
Oct 21,2016: 4SC: Dr Daniel Vitt to step down as CDO/CSO and from the Management Board at the End of 2016
Sep 21,2016: Dr Jason Loveridge appointed new CEO of 4SC
Aug 11,2016: 4SC provides operational and financial update for Q2 and 6M 2016
May 12,2016: 4SC reports on key events in Q1 2016

Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
4SC AG - Key Facts 5
4SC AG - Key Employees 6
4SC AG - Key Employee Biographies 7
4SC AG - Major Products and Services 8
4SC AG - History 9
4SC AG - Company Statement 12
4SC AG - Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
4SC AG - Business Description 14
4SC AG - Corporate Strategy 15
4SC AG - SWOT Analysis 16
SWOT Analysis - Overview 16
4SC AG - Strengths 16
4SC AG - Weaknesses 17
4SC AG - Opportunities 18
4SC AG - Threats 19
4SC AG - Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios - Capital Market Ratios 21
Financial Ratios - Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios - Interim Ratios 25
Financial Ratios - Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27
4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28
4SC AG, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
Nov 10, 2016: 4SC provides Q3 2016 update 30
Oct 21, 2016: 4SC: Dr Daniel Vitt to step down as CDO/CSO and from the Management Board at the End of 2016 32
Sep 21, 2016: Dr Jason Loveridge appointed new CEO of 4SC 33
Aug 11, 2016: 4SC provides operational and financial update for Q2 and 6M 2016 34
May 12, 2016: 4SC reports on key events in Q1 2016 35
Mar 30, 2016: 4SC announces results for financial year 2015 37
Section 6 – Appendix 39
Methodology 39
Ratio Definitions 39
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
4SC AG, Key Facts 5
4SC AG, Key Employees 6
4SC AG, Key Employee Biographies 7
4SC AG, Major Products and Services 8
4SC AG, History 9
4SC AG, Subsidiaries 13
4SC AG, Key Competitors 20
4SC AG, Ratios based on current share price 21
4SC AG, Annual Ratios 22
4SC AG, Annual Ratios (Cont...1) 23
4SC AG, Interim Ratios 25
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27
4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28
4SC AG, Recent Deals Summary 29
Currency Codes 39
Capital Market Ratios 39
Equity Ratios 40
Profitability Ratios 40
Cost Ratios 41
Liquidity Ratios 41
Leverage Ratios 42
Efficiency Ratios 42

List of Figures
4SC AG, Performance Chart (2012 - 2016) 24
4SC AG, Ratio Charts 26
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 28

Companies Mentioned
- SWOG
- MediGene AG
- Galapagos NV
- Biovest International Inc
- Apitope International NV
Date=201707 Topic=SWOTAnalysis Publisher=GlobalData Price=1000